Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RC010
- Development stage
- Phase 1
- Lead developer
- Nanjing Reju Therapeutics
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
RC010 is an inhaled small-molecule inhibitor of Rho-associated protein kinase (ROCK) being developed by Nanjing Reju Therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Formulated as a dry powder for inhalation, the drug is designed to be delivered directly to the lungs, which aims to achieve high local concentrations at the site of fibrotic activity while minimizing systemic exposure and potential off-target effects. The inhibition of ROCK signaling pathways is intended to reduce myofibroblast activation and extracellular matrix deposition, thereby slowing or reversing the progression of pulmonary fibrosis. RC010 is currently in Phase 1 clinical development, with studies focused on evaluating its safety, tolerability, and pharmacokinetic profile in healthy volunteers.
- Other names
- RC010 Inhalation PowderRC-010 Inhalation PowderRC 010 Inhalation Powder
02
Targets
ROCK1 (Rho-associated coiled-coil containing protein kinase 1)ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Beyond the preview
Go deeper on RC010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RC010.